Caveolin-1 related methods for treating glioblastoma with temozolomide

• US 10,022,372 B2
• Filed: 04/18/2014
• Issued: 07/17/2018
• Est. Priority Date: 04/19/2013
• Status: Active Grant

• Current Assignee: Thomas Jefferson University (Main Line Health System)
• Original Assignee: Thomas Jefferson University (Main Line Health System)
• Inventors: Lisanti, Michael P., Jasmin, Jean-Francois, Quann, Kevin
• Primary Examiner(s): West, Theodore R.
• Application Number:
  US14/785,553
• Publication Number:
  US 20160074389A1
• Time in Patent Office: 1,551 Days
• CPC Class Codes: A61K 31/495 having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazinesA61K31/48 takes precedence ; with three nitrogen atoms A61K31/53
• CPC Class Codes: A61N 5/10 X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy A61N5/01 takes precedence
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 2333/705 Assays involving receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: G01N 33/57407 Specifically defined cancers

Abstract

This invention provides a method for treating a subject afflicted with glioblastoma multiforme comprising administering a therapeutically effective regimen of temoxolomide to be glioblastoma multiforme-afflicted subject, wherein the subject'"'"'s glioblastoma multiforme cells are known to be caveolin-1-positive. This invention also provides a method for determining whether a subject afflicted with glioblastoma multiforme is likely to progress therapeutically in response to a therapeutically effective regimen of temoxolomide comprising determining whether the subject'"'"'s glioblastoma multiforme cells are caveolin-1-positive, whereby if the subject'"'"'s glioblastoma multiforme cells are caveolin-1-positive, the subject is likely to progress therapeutically in response to a therapeutically effective regimen of temozolomide.

Claims

1. A method for treating a subject affiliated with glioblastoma multiforme comprising administering a therapeutically effective regime of temozolomide to the glioblastoma multiforme-afflicted subject, concurrently with radiation therapy delivered as 60 Gy/30 fractions and with concomitant administration of Pneumocystis carinii pneumonia prophylaxis during therapy, wherein the subject'"'"'s glioblastoma multiforme cells are caveolin-1 positive.

2. The method of claim 1, wherein the subject is human.

3. The method of claim 2, wherein the glioblastoma multiforme is newly diagnosed in the subject, and wherein the glioblastoma multiforme cells are early apoptotic cells.

4. The method of claim 1, wherein the subject'"'"'s glioblastoma multiforme cells express an amount of caveolin-1 that is a percentage of the amount of caveolin-1 expressed by a lentiviral transduced caveolin-1-overxpressing U-87MG cell.

5. A method for treating a subject affiliated with glioblastoma multiforme comprising;

determining if said subject'"'"'s glioblastoma multiforme cells are determined to be caveolin-1 positive by an antibody-based method;

administering a therapeutically effective regime of temozolomide to the glioblastoma multiforme-afflicted subject, concurrently with radiation therapy delivered as 60 Gy/30 fractions and with concomitant administration of Pneumocystis carinii pneumonia prophylaxis during therapy, wherein the subject'"'"'s glioblastoma multiforme cells are caveolin-1 positive.

6. The method of claim 5, wherein the subject is human.

7. The method of claim 5, wherein the glioblastoma multiforme is newly diagnosed in the subject, and wherein the glioblastoma multiforme cells are early apoptotic cells.

8. The method of claim 5, wherein the subject'"'"'s glioblastoma multiforme cells express an amount of caveolin-1 that is a percentage of the amount of caveolin-1 expressed by a lentiviral transduced caveolin-1-overxpressing U-87MG cell.

9. The method of claim 8, wherein the percentage is above 200%.